Published Online: Monday, January 1, 2007

AstraZeneca has entered into a new supply and distribution agreement with Par Pharmaceutical to distribute an authorized generic version of metoprolol succinate in the United States. Under the arrangement, AstraZeneca will continue to market its branded version of metoprolol succinate, Toprol-XL, throughout the United States.

At least initially, the generic version will be available only in the 25-mg dosage—a strength that represents an estimated 20% of AstraZeneca's Toprol-XL sales in the United States. The agreement between AstraZeneca and Par was announced on the heels of the US launch of a 25-mg version of metoprolol succinate by Sandoz'Eon Labs.

Although patent protection for Toprol-XL does not expire until September 2007, a federal district court declared that patent invalid last year, a ruling that paved the way for Eon's generic version.

Latest Articles
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Latest Issues